Cabazitaxel

Generic Name: Cabazitaxel

Brand Names: Jevtana, Cabazitaxel Accord

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₇NO_₁₄

CAS Number: 183133-96-2

Unique Ingredient Identifier: 51F690397J

Background: Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like paclitaxel and docetaxel.

Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019.

Indication: 用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trials

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: Nivolumab
Drug: Cabazitaxel
Biological: Ipilimumab
Drug: Prednisone

First Posted Date: 2016-12-07

Last Posted Date: 2025-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 351

Registration Number: NCT02985957

Locations: 🇺🇸
Local Institution - 0078, Albany, New York, United States
🇺🇸
Local Institution - 0010, Philadelphia, Pennsylvania, United States
🇩🇰
Local Institution - 0063, Aarhus N, Midtjylland, Denmark

and more 56 locations

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Phase 3

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2016-11-10

Last Posted Date: 2022-05-12

Lead Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Target Recruit Count: 196

Registration Number: NCT02961257

Locations: 🇫🇷
CHU Henri-Mondor, Créteil, France
🇫🇷
Hôpital Universitaire Tenon, Paris, France
🇫🇷
Institut de Cancérologie du Gard - CHU, Nîmes, France

and more 28 locations

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisone
Drug: Radium-223 dichloride
Drug: cabazitaxel
Drug: Carboplatin
Drug: Enzalutamide

First Posted Date: 2016-09-16

Last Posted Date: 2024-02-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 40

Registration Number: NCT02903160

Locations: 🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Hormone-Resistant Prostate Cancer
Stage IV Prostate Adenocarcinoma

Interventions: Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2016-07-26

Last Posted Date: 2021-01-25

Lead Sponsor: University of California, Davis

Target Recruit Count: 2

Registration Number: NCT02844582

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Adenocarcinoma AJCC v7
Castration Levels of Testosterone
PSA Progression

Interventions: Drug: Abiraterone Acetate
Drug: Apalutamide
Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Drug: Cabazitaxel
Drug: Carboplatin
Drug: Prednisone

First Posted Date: 2016-03-09

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 196

Registration Number: NCT02703623

Locations: 🇺🇸
MD Anderson in Katy, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson in Sugar Land, Sugar Land, Texas, United States

Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs

Phase 2

Withdrawn

Conditions: Prostatic Neoplasms

Interventions: Drug: cabazitaxel

First Posted Date: 2015-12-03

Last Posted Date: 2016-08-17

Lead Sponsor: Erasmus Medical Center

Registration Number: NCT02621190

Locations: 🇳🇱
Erasmus MC Cancer Institute, Rotterdam, Netherlands

Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2015-09-25

Last Posted Date: 2020-10-08

Lead Sponsor: Vejle Hospital

Target Recruit Count: 26

Registration Number: NCT02560337

Locations: 🇩🇰
Vejle Hospital, Department of Oncology, Vejle, Denmark

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate with prednisone
Drug: Leuprolide
Drug: Cabazitaxel with peg-filgrastim

First Posted Date: 2015-09-07

Last Posted Date: 2024-01-31

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 76

Registration Number: NCT02543255

Locations: 🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 2 locations

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v7

Interventions: Drug: Cabazitaxel
Drug: Enzalutamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Prednisone

First Posted Date: 2015-08-13

Last Posted Date: 2025-03-14

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 37

Registration Number: NCT02522715

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Portland VA Medical Center, Portland, Oregon, United States

Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer

Phase 2

Completed

Conditions: Bone Metastatic Prostate Cancer

Interventions: Drug: Cabazitaxel

First Posted Date: 2015-07-31

Last Posted Date: 2020-02-10

Lead Sponsor: Hellenic Cooperative Oncology Group

Target Recruit Count: 60

Registration Number: NCT02512458

Locations: 🇬🇷
EUROMEDICA General Clinic of Thessaloniki, Thessaloníki, Thessaloniki, Greece
🇬🇷
Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology, Athens, Greece
🇬🇷
Athens Medical Center, Dept of Medical Oncology, Athens, Maroussi, Greece

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy